Medical Information
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

ATGAM® Adverse Reactions (lymphocyte immune globulin, anti-thymocyte globulin [equine])

6 ADVERSE REACTIONS

The most clinically significant adverse reactions are anaphylaxis, infection, thrombocytopenia, leukopenia, arthralgia, edema, bradycardia, and abnormal renal and liver function tests.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of ATGAM has been evaluated in 367 patients with renal transplant and 109 patients with aplastic anemia.

The renal transplantation and aplastic anemia patients received a similar dosing regimen, and these data were pooled to obtain the frequencies listed in Tables 1 and 2 below.

The most commonly reported adverse reactions (occurring in greater than 10% of patients) are pyrexia, chills, rash, thrombocytopenia, leukopenia and arthralgia.

Table 1. Adverse Reactions Occurring in ≥1% of Patients who Received ATGAM
Adverse Reaction*, ATGAM
Frequency (%)
(N = 476)
*
Percentages are treatment-emergent all-causality events
Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms
Pyrexia 39.5
Chills 26.5
Rash 25.6
Thrombocytopenia 21.6
Leukopenia 17.9
Arthralgia 17.2
Urticaria 9.2
Headache 5.3
Pruritus 4.6
Nausea 4.2
Infection 3.4
Vomiting 3.4
Thrombophlebitis 3.2
Hypertension 2.9
Hypotension 2.9
Diarrhea 2.9
Abdominal pain upper 2.7
Chest pain 2.7
Infusion site pain 2.1
Edema 2.1
Bradycardia 1.5
Back pain 1.5
Lymphadenopathy 1.3
Arteriovenous fistula thrombosis 1.3
Dizziness 1.1
Dyspnea 1.1
Tachycardia 1.1
Liver function test abnormal 1.0
Table 2. Adverse Reactions Occurring in <1% of Patients who Received ATGAM
Adverse Reaction*, ATGAM
Frequency (%)
(N = 476)
*
Percentages are treatment-emergent all-causality events
Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms
Convulsion 0.8
Pleural effusion 0.8
Night sweats 0.8
Serum sickness 0.6
Hyperglycemia 0.6
Stomatitis 0.6
Renal function test abnormal 0.6
Herpes simplex 0.4
Agitation 0.4
Hiccups 0.4
Proteinuria 0.4
Asthenia 0.4
Malaise 0.4
Wound dehiscence 0.4
Anaphylactic reaction 0.2
Encephalitis 0.2
Paresthesia 0.2
Renal artery thrombosis 0.2
Iliac vein occlusion 0.2
Laryngospasm 0.2
Pulmonary edema 0.2
Dermatitis allergic 0.2
Periorbital edema 0.2
Toxic epidermal necrolysis 0.2

6.2 Post-Marketing Experience

The following adverse reactions have been identified during post approval use of ATGAM. Because reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Infections and infestations: Hepatitis viral, Localized infection, Systemic infection

Blood and lymphatic system disorders: Anemia, Eosinophilia, Granulocytopenia, Hemolysis, Hemolytic anemia, Neutropenia, Pancytopenia

Psychiatric disorders: Confusional state, Disorientation

Nervous system disorders: Dyskinesia, Syncope, Tremor

Cardiac disorders: Cardiac failure congestive

Vascular disorders: Deep vein thrombosis, Vasculitis

Respiratory, thoracic and mediastinal disorders: Apnea, Cough, Epistaxis, Oropharyngeal pain

Gastrointestinal disorders: Abdominal pain, Gastrointestinal hemorrhage, Gastrointestinal perforation, Oral pain

Skin and subcutaneous tissue disorders: Hyperhidrosis

Musculoskeletal and connective tissue disorders: Flank pain, Muscle rigidity, Myalgia, Pain in extremity

Renal and urinary disorders: Kidney enlargement, Kidney rupture, Renal failure acute

Congenital, familial and genetic disorders: Aplasia

General disorders and administration site conditions: Infusion site erythema, Infusion site swelling, Pain

 
Did you find an answer to your question? Yes No

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

ATGAM® Quick Finder

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

*9AM-5PM ET Monday to Friday; excluding holidays.

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch